Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

"Differential risk of hospitalization among single virus infections causing influenza-like illnesses".

Ortiz-Hernández AA, Nishimura KK, Noyola DE, Moreno-Espinosa S, Gamiño A, Galindo-Fraga A, Valdéz Vázquez R, Magaña Aquino M, Ramirez-Venegas A, Valdés Salgado R, Andrade-Platas D, Estevez-Jimenéz J, Ruiz-Palacios GM, Guerrero ML, Beigel J, Smolskis MC, Hunsberger S, Freimanis-Hence L, Llamosas-Gallardo B; Mexico Emerging Infectious Diseases Clinical Research Network (La Red).

Influenza Other Respir Viruses. 2018 Aug 23. doi: 10.1111/irv.12606. [Epub ahead of print]

2.

Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.

Hunsberger S, Memoli MJ.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02018-17. doi: 10.1128/AAC.02018-17. Print 2018 Jan. No abstract available.

3.

X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability.

Marciano BE, Zerbe CS, Falcone EL, Ding L, DeRavin SS, Daub J, Kreuzburg S, Yockey L, Hunsberger S, Foruraghi L, Barnhart LA, Matharu K, Anderson V, Darnell DN, Frein C, Fink DL, Lau KP, Long Priel DA, Gallin JI, Malech HL, Uzel G, Freeman AF, Kuhns DB, Rosenzweig SD, Holland SM.

J Allergy Clin Immunol. 2018 Jan;141(1):365-371. doi: 10.1016/j.jaci.2017.04.035. Epub 2017 May 18.

PMID:
28528201
4.

Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization.

Peterson RL, Vock DM, Powers JH, Emery S, Cruz EF, Hunsberger S, Jain MK, Pett S, Neaton JD; INSIGHT FLU-IVIG Study Group.

Clin Trials. 2017 Jun;14(3):264-276. doi: 10.1177/1740774517697919. Epub 2017 Mar 6.

5.

Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Ferre EM, Rose SR, Rosenzweig SD, Burbelo PD, Romito KR, Niemela JE, Rosen LB, Break TJ, Gu W, Hunsberger S, Browne SK, Hsu AP, Rampertaap S, Swamydas M, Collar AL, Kong HH, Lee CR, Chascsa D, Simcox T, Pham A, Bondici A, Natarajan M, Monsale J, Kleiner DE, Quezado M, Alevizos I, Moutsopoulos NM, Yockey L, Frein C, Soldatos A, Calvo KR, Adjemian J, Similuk MN, Lang DM, Stone KD, Uzel G, Kopp JB, Bishop RJ, Holland SM, Olivier KN, Fleisher TA, Heller T, Winer KK, Lionakis MS.

JCI Insight. 2016 Aug 18;1(13). pii: e88782.

6.

A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries.

Godfrey C, Tauscher G, Hunsberger S, Austin M, Scott L, Schouten JT, Luetkemeyer AF, Benson C, Coombs R, Swindells S; HIV Network Coordinating (HANC) TB Diagnostic Laboratory Working Division of AIDS, National Institute of Allergy and Infectious Diseases.

BMC Infect Dis. 2016 Jun 10;16:269. doi: 10.1186/s12879-016-1579-y.

7.

Clinical characteristics of asthmatic patients with influenza-like illness and risk of severe exacerbations in Mexico.

Paulin-Prado P, Nishimura K, Freimanis-Hance L, Hunsberger S, Beigel J, Fraga AG, Ortiz Hernandez AA, Llamosas-Gallardo B, Moreno-Espinosa S, Magaña-Aquino M, Ruiz Palacios GM, Ramirez-Venegas A; Mexico Emerging Infectious Diseases Clinical Research Network.

Ann Allergy Asthma Immunol. 2016 May;116(5):402-7. doi: 10.1016/j.anai.2016.03.007. Epub 2016 Apr 1.

8.

A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma.

Colombo RE, Fiorentino C, Dodd LE, Hunsberger S, Haney C, Barrett K, Nabha L, Davey RT Jr, Olivier KN.

BMC Infect Dis. 2016 Feb 1;16:54. doi: 10.1186/s12879-016-1358-9.

9.

Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team.

LoRusso PM, Boerner SA, Pilat MJ, Forman KM, Zuccaro CY, Kiefer JA, Liang WS, Hunsberger S, Redman BG, Markovic SN, Sekulic A, Bryce AH, Joseph RW, Cowey CL, Fecher LA, Sosman JA, Chapman PB, Schwartz GK, Craig DW, Carpten JD, Trent JM.

Mol Cancer Ther. 2015 Aug;14(8):1962-71. doi: 10.1158/1535-7163.MCT-15-0153. Epub 2015 Jun 10.

10.

The role of age on dose-limiting toxicities in phase I dose-escalation trials.

Schwandt A, Harris PJ, Hunsberger S, Deleporte A, Smith GL, Vulih D, Anderson BD, Ivy SP.

Clin Cancer Res. 2014 Sep 15;20(18):4768-75. doi: 10.1158/1078-0432.CCR-14-0866. Epub 2014 Jul 15.

11.

Approaches to retrospective sampling for longitudinal transition regression models.

Hunsberger S, Albert PS, Thoma M.

Stat Interface. 2014;7(1):75-85.

12.

Response.

Hunsberger S, Rubinstein L, Boerner SA, LoRusso P.

J Natl Cancer Inst. 2013 Jul 3;105(13):993-4. doi: 10.1093/jnci/djt126. Epub 2013 May 30. No abstract available.

13.

Developing safety criteria for introducing new agents into neoadjuvant trials.

DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L.

Clin Cancer Res. 2013 Jun 1;19(11):2817-23. doi: 10.1158/1078-0432.CCR-12-2620. Epub 2013 Mar 7. Review.

14.

Expression of Gli1 in the hedgehog signaling pathway and breast cancer recurrence.

Takebe N, Hunsberger S, Yang SX.

Chin J Cancer Res. 2012 Dec;24(4):257-8. doi: 10.3978/j.issn.1000-9604.2012.09.07. No abstract available.

15.

Integrated phase II/III clinical trials in oncology: a case study.

Wang M, Dignam JJ, Zhang QE, DeGroot JF, Mehta MP, Hunsberger S.

Clin Trials. 2012 Dec;9(6):741-7. doi: 10.1177/1740774512464724. Epub 2012 Nov 22. Review.

PMID:
23180870
16.

Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.

Gupta S, Hunsberger S, Boerner SA, Rubinstein L, Royds R, Ivy P, LoRusso P.

J Natl Cancer Inst. 2012 Dec 19;104(24):1860-6. doi: 10.1093/jnci/djs439. Epub 2012 Nov 19.

PMID:
23169991
17.

Triple negative breast cancer: breast cancer research in evolution.

Eng-Wong J, Hunsberger S, Zujewski JA.

Breast Dis. 2010;32(1-2):1-4. doi: 10.3233/BD-2010-0314. No abstract available.

PMID:
21778576
18.

Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?

Lorusso PM, Boerner SA, Hunsberger S.

J Clin Oncol. 2011 Aug 1;29(22):2952-5. doi: 10.1200/JCO.2011.36.1311. Epub 2011 Jun 27. No abstract available.

PMID:
21709201
19.

Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.

Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC; Gynecologic Cancer Intergroup/National Cancer Institute Writing Committee, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L.

Int J Gynecol Cancer. 2010 Oct;20(7):1290-8. doi: 10.1111/IGC.0b013e3181ee1c01. Review.

20.

Analysis of progression-free survival data using a discrete time survival model that incorporates measurements with and without diagnostic error.

Hunsberger S, Albert PS, Dodd L.

Clin Trials. 2010 Dec;7(6):634-42. doi: 10.1177/1740774510384887. Epub 2010 Nov 25.

PMID:
21109582

Supplemental Content

Loading ...
Support Center